CELL & GENE THERAPY

Cell & Gene Therapy, Friday 2 March 2018

09:00

Organiser's Welcome Remarks

09:05

Chair's Opening Remarks

Disruption & Digitalisation

09:10

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
 
09:30

CAR-T therapy, the next miracle drug in the making

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. However, the rapid advances still stir fears about the safety of the drug after failed cases and deaths on some pharma sponsored trials. With more companies putting their CAR-T pipeline to test in the market, how can regulators ensure patient safety? And from a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Even if it becomes fully approved for commercial deployment, what needs to be done to help patients afford the sky high cost of immunotherapy?
 
Ivor Lim
09:50

Working with increasingly informed and empowered patients in the digital ageEducated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.
10:10

Exhibition Visit & Networking Refreshments

GENE THERAPY

Cell & Gene Therapy
11:00

Chair's Opening Remarks

Cell & Gene Therapy
11:10

Using CRISPR to remove HIV genes

  • Scientists at Temple University were able to cut out HIV genes from animal models with a 50% success rate.
  • What’s next?
  • What are the concerns and consequences if applied on human subjects?
Cell & Gene Therapy
11:30

Safety considerations in using gene therapy in human cancer treatment

The US NIH recently approved the first in human project to modify the immune cells of 18 different cancer patients. The main focus of this test is to decide on the safety of CRISPR technology on human subjects. Before we discuss on using CRISPR in cancer treatment, how safe is the technology on human? What have we learnt so far from these studies?
Cell & Gene Therapy
11:50

Gene therapy trial in Asia oncology studies and treatment

A high stakes, first in human trial using CRISPR to treat lung cancer was kick-started in China. There are also some researchers claiming gene-editing alternatives to CRISPR-edit DNA in human embryos. What were the results and how can we learn from them as we work to drive CRISPR forward?
 
12:10

Exhibition Visit & Networking Lunch

CELL THERAPIES: MANUFACTURING

Cell & Gene Therapy
13:40

Chair's Opening Remarks

Cell & Gene Therapy
13:45

Coping with manufacturing variability in producing personalised medicine

  • Defining critical process parameters and critical attributes of emerging therapeutics 
  • Discussing current challenges in manufacturing and logistics of personalised medicine
  • How can emerging technologies including IoT, AI and more help in potentially overcoming these challenges?
Panel discussion
Cell & Gene Therapy
14:05

Panel: Selecting the right model for GMP of cell therapy products

  • Balancing cost and quality of centralised vs decentralise manufacturing of CAR-T products
  • Flexible strategies in optimising speed and cost to deliver multi modal product portfolio
  • Key preparations required in keeping up with emerging therapeutic portfolio
  • Case study on fully single use, real time monitoring production facility in Asia
  • Comparing in-house manufacturing vs outsourcing in Asia C
  • Is licensing a good alternative in manufacturing cell therapy products?
14:45

Exhibition Visit & Networking Refreshments

BEYOND CAR-T

Cell & Gene Therapy
15:35

What’s next after CAR-T in Leukaemia treatment?

CAR-T cell therapy is a combination of cell, gene and immunotherapy and it is finally here, to serve as an alternative cancer treatment. Starting with Leukaemia, CAR-T has been tested on solid tumours, genetic diseases and more. What’s Asia role in the CAR-T I-O field and how do we keep up with global trends? 
Cell & Gene Therapy
15:55

CAR-T Therapy: Keeping pace with severe adverse effects

  • Understanding the underlying mechanism of CAR-T therapy
  • Discovering alternative preclinical models for toxicity studies
  • Strategies to further refine our approach and therapy mechanism
Prathibha Shetty
Cell & Gene Therapy
15:55

Case study: What it takes to achieve commercial success for cell & gene therapy products

The uphill path towards commercial success of cell & gene therapy is costly and time extensive. So how do we get there?
Prathibha Shetty, Head, Regenerative Medicine Group, Reliance Life Sciences

Close of Phar-East 2018

last published: 20/Nov/17 06:25